Daniel Gomez

Dr. Daniel Gomez


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in The Lancet Oncology
Verified
Journal Article
Open access
DGDaniel Gomez
Daniel Gomez
GBGeorge R Blumenschein
George R Blumenschein
JLJ Jack Lee
J Jack Lee
MHMike Hernandez
Mike Hernandez
RYRong Ye
Rong Ye
JHJohn V Heymach
John V Heymach
Evidence from retrospective studies suggests that disease progression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at sites of disease known to exist at baseline. However, the potential effect of aggressive local consolidative therapy for patients with oligometastatic NSCLC is unknown. We aimed to assess the effect of local consolidative therapy on progression-free survival. In this multicentre, randomised, controlled, phase 2 study, eligible patients from three hospitals had histological confirmation of stage IV NSCLC, three or fewer metastatic disease lesions after first-line systemic therapy, an Eastern Cooperative Oncology Group performance status score of 2 or less, had received standard first-line systemic therapy, and had no disease progression before randomisation. First-line therapy was four or more cycles of platinum doublet therapy or 3 or more months of EGFR or ALK inhibitors for patients with EGFR mutations or ALK rearrangements, respectively. Patients were randomly assigned (1:1) to either local consolidative therapy ([chemo]radiotherapy or resection of all lesions) with or without subsequent maintenance treatment or to maintenance treatment alone, which could be observation only. Maintenance treatment was recommended based on a list of approved regimens, and observation was defined as close surveillance without cytotoxic treatment. Randomisation was not masked and was balanced dynamically on five factors: number of metastases, response to initial therapy, CNS metastases, intrathoracic nodal status, and EGFR and ALK status. The primary endpoint was progression-free survival analysed in all patients who were treated and had at least one post-baseline imaging assessment. The study is ongoing but not recruiting participants. This study is registered with ClinicalTrials.gov, number NCT01725165. Between Nov 28, 2012, and Jan 19, 2016, 74 patients were enrolled either during or at the completion of first-line systemic therapy. The study was terminated early after randomisation of 49 patients (25 in the local consolidative therapy group and 24 in the maintenance treatment group) as part of the annual analyses done by the Data Safety Monitoring Committee of all randomised trials at MD Anderson Cancer Center, and before a planned interim analysis of 44 events. At a median follow-up time for all randomised patients of 12·39 months (IQR 5·52-20·30), the median progression-free survival in the local consolidative therapy group was 11·9 months (90% CI 5·7-20·9) versus 3·9 months (2·3-6·6) in the maintenance treatment group (hazard ratio 0·35 [90% CI 0·18-0·66], log-rank p=0·0054). Adverse events were similar between groups, with no grade 4 adverse events or deaths due to treatment. Grade 3 adverse events in the maintenance therapy group were fatigue (n=1) and anaemia (n=1) and in the local consolidative therapy group were oesophagitis (n=2), anaemia (n=1), pneumothorax (n=1), and abdominal pain (n=1, unlikely related). Local consolidative therapy with or without maintenance therapy for patients with three or fewer metastases from NSCLC that did not progress after initial systemic therapy improved progression-free survival compared with maintenance therapy alone. These findings suggest that aggressive local therapy should be further explored in phase 3 trials as a standard treatment option in this clinical scenario. MD Anderson Lung Cancer Priority Fund, MD Anderson Cancer Center Moon Shot Initiative, and Cancer Center Support (Core), National Cancer Institute, National Institutes of Health.

1 May 2015 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DGDaniel Gomez
Daniel Gomez
KLKai-Ping Liao
Kai-Ping Liao
SSStephen G. Swisher
Stephen G. Swisher
GBGeorge R. Blumenschein
George R. Blumenschein
JEJeremy J. Erasmus
Jeremy J. Erasmus
BSBenjamin D. Smith
Benjamin D. Smith

1 November 2011 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DGDaniel Gomez
Daniel Gomez
CECherry L. Estilo
Cherry L. Estilo
SWSuzanne L. Wolden
Suzanne L. Wolden
MZMichael J. Zelefsky
Michael J. Zelefsky
DKDennis H. Kraus
Dennis H. Kraus
NLNancy Y. Lee
Nancy Y. Lee

1 February 2013 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
DGDaniel Gomez
Daniel Gomez
DHDavid S. Hong
David S. Hong
PAPamela K. Allen
Pamela K. Allen
JWJames S. Welsh
James S. Welsh
RMReza J. Mehran
Reza J. Mehran
DRDavid C. Rice
David C. Rice
Introduction We investigated safety, efficacy, and recurrence after postoperative hemithoracic intensity-modulated radiation therapy (IMRT) in patients with malignant pleural mesothelioma treated with extrapleural pneumonectomy (EPP), during the past decade at a single institution. Methods In 2001–2011, 136 consecutive patients with malignant pleural mesothelioma underwent EPP with planned adjuvant IMRT. Eighty-six patients (64%) underwent hemithoracic IMRT; the rest were not eligible because of postoperative complications, disease progression, or poor performance status. We assessed toxicity, survival, and patterns of failure in these 86 patients. Toxicity was scored with the Common Terminology Criteria for Adverse Events version 4.0; survival outcomes were estimated with the Kaplan–Meier method; and locoregional patterns of failure were classified as in-field, marginal, or out-of-field. Risk factors related to survival were identified by univariate and multivariate Cox regression analysis. Results Median overall survival time for all 86 patients receiving IMRT was 14.7 months. Toxicity rates of grade of 3 or more were: skin 17%, lung 12%, heart 2.3%, and gastrointestinal toxicity 16%. Five patients experienced grade 5 pulmonary toxicity. Rates of locoregional recurrence-free survival, distant metastasis-free survival, and overall survival (OS) were 88%, 55%, and 55% at 1 year and 71%, 40%, and 32% at 2 years. On multivariate analysis, pretreatment forced expiratory volume in 1 second, nonepithelioid histology, and nodal status were associated with distant metastasis-free survival and OS. Conclusion IMRT after EPP is associated with low rates of locoregional recurrence, though some patients experience life-threatening lung toxicity. Tumor histology and nodal status can be helpful in identifying patients for this aggressive treatment.

1 September 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JGJose Luis Lopez Guerra
Jose Luis Lopez Guerra
DGDaniel Gomez
Daniel Gomez
YZYan Zhuang
Yan Zhuang
DHDavid S. Hong
David S. Hong
JHJohn V. Heymach
John V. Heymach
ZLZhongxing Liao
Zhongxing Liao

1 July 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
DGDaniel Gomez
Daniel Gomez
RKRitsuko Komaki
Ritsuko Komaki
JYJames Yu
James Yu
HIHitoshi Ikushima
Hitoshi Ikushima
ABAndrea Bezjak
Andrea Bezjak